cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mustofa
Contact Email
mustofafk@ugm.ac.id
Phone
+6281328749273
Journal Mail Official
mustofafk@ugm.ac.id
Editorial Address
Department of Pharmacology and Therapy Radioputro Building 2nd Floor Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281 Indonesia
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.10147
Core Subject : Health, Science,
Immunology & microbiology Medicine & Pharmacology
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which published by Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI). IJPTher is an open-access, and double-blind peer-reviewed journal published three Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 107 Documents
 7   8   9   10   11 
Adverse effects of fentanyl/midazolam among patients of intensive care unit (ICU): a narrative review Septiyanti, Windy; Puspita Sari, Ika; Murti Andayani, Tri
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11232

Abstract

Patients of intensive care unit (ICU) have a complicated condition due to disease, comorbid, and other risk factors. Some ICU patients need to get an invasive process to reduce pain, anxiety, and support their condition. During an invasive process, including mechanical ventilation which causes pain or anxiety, the patient is givensedative and analgesic agents to support the procedure and reduce the patient’s pain and anxiety. However, the use of fentanyl/midazolam has the potential to cause adverse effects, for instance, hypotension, hypoxia, and delirium in several ICU patients. Several risk factors that can lead to adverse effects are aging, obesity, underlying cardiac disease, and the amount of dosage. Therefore, it is essential to recognize the risk factors and monitor the use of fentanyl/midazolam to prevent the worsening condition of patients.
Current Advances in Triple-Negative Breast Cancer (TNBC) Chemotherapy: A Literature Review Murwanti, Retno; Rommy; Nugroho, Agung Endro
Indonesian Journal of Pharmacology and Therapy Vol 5 No 3 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11403

Abstract

Triple-negative breast cancer (TNBC) is one of subtypes of cancer with the most associated death. With more than 20% of breast cancer patients having this subtype, an effective and safe chemotherapy is needed to ensure complete pathomorphological response. Currently, therapies for TNBC patients are divided into systemic therapy regimens for operable or non-operable diseases, with non-operable diseases mostly treated with targeted therapies such as pembrolizumab in tandem with other chemotherapy agents such as paclitaxel, gemcitabine or carboplatin. TNBC patients whom tumor is operable underwent additional step such as preoperative systemic therapy, which offers several advantages than chemotherapy alone. Neoadjuvant chemotherapy (NACT), which consist of mainly drugs from therapeutic classes such as anthracycline and taxanes, is used with limited success (23%) and decreased recurrence rates. Optimal method for treating TNBC is still lacking, therefore the need for further research regarding chemotherapy for TNBC with higher success rate and better prognosis for the patients is paramount.
Coral plant (Jatropha multifida L) leaf extracts inhibit dengue virus-2 (DENV-2) growth through NS5 Yuniyanti, Mia Munawaroh; Sri Hartati Wahyuningsih, Mae
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11410

Abstract

The incidence of dengue fever (DF) increases drastically from year to year, especially in tropical countries like Indonesia. In contrast, antiviral against dengue virus (DENV) is not available in clinics, yet. Jatropha multifica L, locally named tanaman yodium/coral plant, is a medicinal plant that is traditionally used to treat dengue hemorrhagic fever (DHF). However, its scientific evidence is limited. This study aimed to investigate the antiviral activity of J. multifida L leaf extracts against DENV-2 and evaluate the effect on NS5 RNA expression. The leaf extracts were prepared by multilevel extraction using chloroform and methanol. The study was conducted in vitro using DEN-2 and Vero cells. The antiviral activity was assessed by using qRT-PCR to assess the number of virus copies and then used to calculate the inhibitory concentration of 50% (IC50). The effect of the most active extract on NS5 DENV-2 RNA expression was then evaluated by using qRT-PCR. Among 4 extracts tested, the methanolic insoluble chloroformic extract (MIS) is the most active with an IC50 value of 124.3 μg/mL. Furthermore, the MIS (0.02) strongly inhibited NS5 DENV-2 RNA expression compared to control (1.0). In conclusion, the MIS of J. multifida is active against DENV-2 through inhibition of NS5 RNA expression.
Cytotoxicity of quercetin and curcumin combination against HeLa cells line Agitohutomo, Muhammad; Edityaningrum, Citra Ariani; Utari, Dina; Desvita, Widea Rossi; Aristiani, Windi; Nurani, Laela Hayu
Indonesian Journal of Pharmacology and Therapy Vol 5 No 1 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11488

Abstract

Curcumin and quercetin combination are potential candidates for anticancer. Previous studies reported this combination active against several cancer cells including breast cancer, myeloid leukemia, and melanoma. However, the activity of this combination against cervical cancer has not been reported, yet. This study aimed to evaluate the cytotoxicity of the combination of curcumin and quercetin against HeLa and Vero cells. MTT assay was applied to evaluate cell growth inhibition. The inhibitory 50% concentration (IC50) of curcumin and quercetin on HeLa and Vero cells was determined and the selectivity index (SI) was then calculated. Combination index (CI) was calculated after evaluation of the cytotoxicity of the curcumin and quercetin combination at various concentration of 1 IC50, ½ IC50, and ¼ IC50. The IC50 of the curcumin against the HeLa and Vero cells were 26.57 ± 2.00 μM and 73.89 ± 12.93 μM with a SI of 2.78. Whereas the IC50 of the quercetin against the HeLa and Vero cells were 149.52 ± 21.09 μM and 1094.47 ± 15.68 μM with a SI of 7.32. The CI of combinations of curcumin and quercetin at concentrations of ¼ IC50 was 0.78 indicating a mild-moderate synergistic effect, whereas the combination at a concentration of 1 IC50 or ½ IC50, the CI value was >0.9 indicating an antagonistic effect.
Topical gel preparation from Staphylococcus epidermidis isolate extract accelerated healing on incision wound model in rats Mochtar, Chaerul Fadly; Bakhtiar, Muh Irham; Hamzah, Hasyrul; Pratama, Aldo; Rasyidah, Jamiatur; Indriyani, Juniar Rakhmatia; Alfiannur, Muhammad Rizky; Amalia, Nadhifah Suci; Putri, Nur Octaviany; Damis, Nur Lutfiah
Indonesian Journal of Pharmacology and Therapy Vol 5 No 1 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11510

Abstract

A wound is a disorder of skin integrity caused by physical trauma or disease. Wound healing is a natural restorative response to tissue injury. It is a complex dynamic physiological process involving several overlapping phases. Although wound management has been applied, however, some time it is associated withmajor drawbak including invasiveness, antibiotic resistance, and high costs. Natural medicines are being developed for wound management to resolve the drawback. Commensal Staphylococcus epidermidis was proven to play a role in natural wound healing process. This study aimed to investigate the wound healingactivity of a topical gel preparation containing S. epidermidis isolate extract on an incision wound model in rats. The methanol extract of S. epidermidis isolate was prepared by maceration and used as an active ingredient of the topical gel using NaCMC as a gelling agent. A physical stability test was carried out by assessingorganoleptic properties, pH value, homogeneity, dispersion, and viscosity of the gel preparation. The gel preparation was then topically applied once-daily for 11 d on incision wound model of male white rats (Rattus norvegicus). The wound healing was observed daily and calculated using Morton’s formula. Nosignificant change in the physical stability parameters of the gel preparation was observed during observation on day 1, 7, and 14 (p>0.05). A significant increase in wound healing after the application of the gel preparation compared to negative control was observed (p<0.05). In contrast, no significant difference inwound healing between the gel preparation and the positive control group was observed (p>0.05). In conclusion, the topical gel preparation from S. epidermidis isolate extract accelerates healing on incision wound models in rats.
Comparison ondansetron and domperidon as antiemetic for gastroenteritis in children: a review Siregar, Mardiana; Wiedyaningsih, Chairun; Mutiara, Rina
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11716

Abstract

Gastroenteritis (GE) is the leading cause of vomiting in children. It is the main reason children admitted into emergency departments (EDs). Vomiting can cause fluid loss therefore oral rehydration solution (ORT) is recommended as supportive care for mild to moderate dehydration. Antiemetic therapy for GE is not fully recommended by any management guidelines. However, in some studies, antiemetics including ondansetron and domperidone are used in vomiting-related GE. This review aimed to compare ondansetron and domperidone for the treatment of GE in children. The article search was performed to identify relevant publications using PubMed database PubMed. PRISMA flow diagram was used as protocol during the article screening process. Eight
Tamarindus indica increases the stability of jamu kunyit-asam herbal suspension over Citrus aurantifolia wicaksono, arko jatmiko; Rakhmawati, rita; Wahyuningsih, Mae Sri Hartati; Syarif, Rul Afiyah; Prasetyo, Yacobus Christian
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11818

Abstract

Rapid shelf-life of traditional supplementary drink still becomes major issue for herbal production in household industries. In this study the stability formula of an herbal suspension, so called as jamu kunyit-asam, was investigated. The jamu kunyit-asam Formula-1 (F1) contains combination of Citrus aurantifolia and Curcuma longa. While the Formula-2 (F2) is consisted by mixture of Tamarindus indica and C. longa. The two formulas were compared to justify better stability between preparations. No preservatives were added, in order to comply with the local regulation. To simulate the real situation, all samples were stored in 4 different conditions: opened bottle (room temperature), closed bottle (room temperature), closed bottle (refrigerator), and freeze-thaw condition. To evaluate the stability profile, an organoleptic testing and pH alteration were frequently checked for 12 consecutive days. Several parameters including color changing, sting odor, and microscopic appearance were looked over. As the results, mold, precipitation and pungent odor were formed faster from the F1 (C. aurantifolia combined with C. longa). These findings indicates that jamu kunyit-asam herbal drink suspensions containing C. longa has less stability in combination with the C. aurantifolia (F1) compared to the T. indica (F2).
Weight growth velocity in low birth weight neonates receiving parenteral nutrition in the Neonatal Intensive Care Unit, Kandou General Hospital, Manado 2022: a retrospective observational study Kukihi, Farha Elein; Wiedyaningsih, Chairun; Rina Mutiara
Indonesian Journal of Pharmacology and Therapy Vol 5 No 3 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.12442

Abstract

Neonates with low birth weight (LBW) have a higher risk of growth failure. To optimize their growth to target of 15-20 g/kg/d, neonates must receive adequate nutrition. Parenteral nutrition implementation is one of the approaches to provide adequate energy and nutrition to LBW neonates who can not tolerate enteral feeding. This study aims to investigate growth velocity in LBW neonates receiving parenteral nutrition in hospital settings and observe if the target growth velocity was achieved, also describes current parenteral nutrition practices in tertiary hospital settings. A retrospective observational study was conducted in the Neonatal Intensive Care Unit (NICU), Kandou General Hospital, Manado. Sample in this study were neonates with birth weight <2500 g and received only parenteral nutrition for minimum 7 d. Daily weight measurement data was collected through medical records and parenteral nutrition regimens was collected through electronic prescriptions in the Pharmacy Department. Growth velocity was assessed using two parameters, gain weight velocity and change in weight for age Z-scores (WAZ). A total of 73 neonates were used as samples. The results demonstrated that only the extremely low birth weight (ELBW) group achieved the growth velocity recommendation during parenteral nutrition, 16.17 g/kg/d. All the neonates had a negative change of weight Z-scores indicated a declining growth rate during parenteral nutrition administration. We also found lipid emulsion initiation time was later and relatively low energy intake in parenteral nutrition compared to the recommendation. Vitamin as micronutrient was not yet added in parenteral nutrition regimens. Therefore, we suggest starting lipid emulsion from the first day of parenteral nutrition and add vitamin to parenteral nutrition regimen to optimize nutrient intake in order to improve growth velocity in LBW neonates during NICU stay.
Biomarkers improving decisions making in clinical trials: explanations and examples Faiha, Dhea Kirana; Lupitasari, Florentina Bety Indah; Fitria, Humairah; Salamah, Umi; Supriyati, Vidia Ajeng
Indonesian Journal of Pharmacology and Therapy Vol 5 No 3 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.13088

Abstract

Biomarkers are originate from physiological processes, medical imaging, tissues, or chemicals. They are potentially useful indicators for every type of disease and have important roles on drug discovery and development, disease progression tracking, prognosis, diagnosis, and therapy response. Biomarkers provide precision measurement results, lower bias result, also faster early warning signal. Therefore, they can be used as a basis for clinical decisions. Biomarkers found in tissues, blood, and other bodily fluids. Depend on their purpose of usage, biomarkers can be categorized of diagnostic, prognostic to predicts disease progression, pharmacodynamic to measures the effect of a drug on a biological system, and predictive to predicts response to a specific treatment. In clinical trials, biomarker can be used as basic of decisions making. Therefore, several steps required to incorporate biomarkers in clinical trials are determine roles and functions of biomarkers, choose specific test and laboratory according to purpose of trial, describe test and protocol, carry out and report analysis validation appropriate for trial, implement test in trial, and plan sustainability of biomarker uses in future research. Biomarker have been used as basis of decision making in clinical trials in phase I-IV to recruit participants or making a decision whether the trial will be terminated or continued. In this review, we outlined general explanations about molecular biomarkers, step of biomarkers incorporation in clinical trial, and examples of several studies using molecular biomarkers in clinical trial as basis of decision-making.
Antiemetic prophylaxis utilization in cancer patients in a hospital in Yogyakarta Special Region Faridah, Imaniar Noor; Dyah Aryani Perwitasari; Siswandi; Lamhot B Simanjuntak; Suhendra, Gugun; Wulandari, Dewi; Dania, Haafizah; Rizky, Muhammad Arif; Islami, Safira Nur; Fatimah, Salma Auliya
Indonesian Journal of Pharmacology and Therapy Vol 5 No 3 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.14243

Abstract

Chemotherapy is a type cancer treatment that uses anticancer drugs to inhibit cell division and kill cancer cells. Chemotherapy can cause side effect due to normal cells damages. The study aimed to investigate the use of antiemetic prophylaxis as premedication to prevent or reduce side effects on cancer patients undergoing chemotherapy. It was a observational study with retrospective design using medical records data of cancer patients who underwent chemotherapy in a hospital in Yogyakarta Special Region during May – September 2022. The results showed the cancer patients were dominated by women (85.71%) with ages 46-65 yr (63.27%) and stage III cancer (87.76%). There were 18 types of anticancer drugs and the most widely used drugs were doxorubicin 60 mg for the moderate emetogenic category and vinorelbine 37.5 mg for the low emetogenic category. The most widely used premedication regimen was a combination granisetron 3 mg, ondansetron 8 mg, and dexamethasone 10 mg regimen (72.45%). This combination was most often used for the cancer patients with the moderate emetogenic category (39 patients or 49.4%). However, not all the cancer patients undergoing chemotherapy with the low and moderate emetogenic anticancer drugs were administered the premedication. In conclusion, doxorubicin and vinorelbine are the most widely used for cancer patients undergoing chemotherapy in the hospital. In addition, a combination of granisetron, ondansetron, and dexamethasone is widely used as premedication.

Page 9 of 11 | Total Record : 107

 7   8   9   10   11 

Filter by Year

2020 2025


Reset
Filter By Issues
All Issue Vol 6 No 3 (2025) Vol 6 No 2 (2025) Vol 6 No 1 (2025) Vol 5 No 3 (2024) Vol 5 No 2 (2024) Vol 5 No 1 (2024) Vol 4 No 3 (2023) Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue